Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Impact BioMedicalIBO -1.57%10 Days Payable is 38,370.63 as of Jun. 2026, which is 13387% above its 10-year median of 284.51. GuruFocus rates IBO with a GF Score™ of 10/100. The stock has 6 warning signs investors should review. Among 704 Biotechnology companies, Impact BioMedical ranks better than 75% on this metric.
The historical rank and industry rank for Impact BioMedical's Days Payable or its related term are showing as below:
IBO'
s Days Payable Range Over the Past 10 Years
Min: 284.51 Med: 284.51 Max: 399.09
Current: 399.09
During the past 7 years, Impact BioMedical's highest Days Payable was 399.09. The lowest was 284.51. And the median was 284.51.
IBO's Days Payable is ranked better than 75% of 704
companies
in the Biotechnology industry
Industry Median: 112.715
vs IBO: 399.09
Impact BioMedical's Days Payable
declined
from Jun. 2025 (53,335.63) to Jun. 2026 (38,370.63).
It may suggest that Impact BioMedicalaccelerated paying its suppliers.
The historical data trend for Impact BioMedical's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Impact BioMedical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Impact BioMedical Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Impact BioMedical's Days Payable distribution charts can be found below:
* The bar in red indicates where Impact BioMedical's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Impact BioMedical's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Impact BioMedical (IBO) has a Days Payable of 38,370.63 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Impact BioMedical and its competitors. This is 13387% above median its historical median of 284.51. Over the past decade, Impact BioMedical's Days Payable has ranged from 284.51 to 399.09. According to the industry distribution chart, Impact BioMedical ranks #176 out of 704 companies in the Biotechnology industry, placing it in the top 25%.
Is Impact BioMedical's Days Payable too high?
Impact BioMedical's current Days Payable of 38,370.63 is 13387% above median its 10-year median of 284.51. Over the past 10 years, this metric has ranged from a low of 284.51 to a high of 399.09. The Biotechnology industry median Days Payable is 112.72. Impact BioMedical's value of 38,370.63 is 33942.2% above this industry median. Based on the distribution chart, Impact BioMedical ranks #176 out of 704 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Impact BioMedical has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Impact BioMedical's Days Payable compare to ATYR and MCRB?
According to the Biotechnology industry distribution chart, Impact BioMedical ranks #176 out of 704 companies for Days Payable. This places Impact BioMedical in the top 25% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.72. Impact BioMedical's value of 38,370.63 is 33942.2% above this benchmark. Historically, Impact BioMedical's own Days Payable has ranged from 284.51 to 399.09 over the past decade. While the company's 10-year median is 284.51 vs. the industry median of 112.72, Impact BioMedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Impact BioMedical's current Days Payable of 38,370.63 is 33942.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Impact BioMedical and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Impact BioMedical's current Days Payable is 38,370.63, which is 13387% above median its own 10-year median of 284.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impact BioMedical stock overvalued right now?
Impact BioMedical (IBO) has a current Days Payable of 38,370.63. The current Days Payable is 38,370.63, which is 13387% above median its 10-year median of 284.51 and 33942.2% above the Biotechnology industry median of 112.72. Impact BioMedical's overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Impact BioMedical (IBO), the current Days Payable is 38,370.63 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
10GF Score
Get the complete analysis for IBO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IBO has been successfully added to your 
